

Ref: Akums/Exchange/2026-27/05

8<sup>th</sup> May, 2026

**To,**  
**The Listing Department**  
**National Stock Exchange of India Ltd.**  
**Exchange Plaza, C-1, Block G,**  
**Bandra Kurla Complex,**  
**Bandra (E), Mumbai - 400 051**

**To,**  
**The Listing Department**  
**BSE Limited**  
**25th Floor, New Trading Ring,**  
**Rotunda Building, Phiroze Jeejeebhoy**  
**Towers, Dalal Street, Mumbai - 400 001**

**Symbol: AKUMS**

**Scrip Code: 544222**

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - ESG Rating**

Respected Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30<sup>th</sup> January, 2026, this is to inform you that on 7<sup>th</sup> May, 2026, the Company has received an ESG rating of "63" for the Financial Year 2024-25 from NSE Sustainability Ratings & Analytics Limited ("NSE Sustainability"), a subsidiary of NSE Indices Limited and a registered ESG Rating Provider.

Please be informed that the Company has not engaged NSE Sustainability for ESG Rating and they have voluntarily assigned the aforesaid ESG Rating on the basis of publicly available information. The link of the ESG rating is <https://www.nse-esgrating.com/esg-ratings/552?fiscalYear=2024-2025>

This is for your kind information and record.

Thanking You

Yours Faithfully  
For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik  
Company Secretary & Compliance Officer